Updates are available Correction dated 2023-12-04
Click to view Correction: https://doi.org/10.1038/s41591-023-02735-4
-
Authors
Baca, Sylvan C.
Seo, Ji-Heui
Davidsohn, Matthew P.
Fortunato, Brad
Semaan, Karl
Sotudian, Shahabbedin https://orcid.org/0000-0002-5864-6192
Lakshminarayanan, Gitanjali
Diossy, Miklos
Qiu, Xintao https://orcid.org/0000-0002-8560-7017
El Zarif, Talal
Savignano, Hunter
Canniff, John
Madueke, Ikenna
Saliby, Renee Maria https://orcid.org/0000-0002-9241-597X
Zhang, Ziwei
Li, Rong https://orcid.org/0009-0000-1046-9580
Jiang, Yijia
Taing, Len
Awad, Mark
Chau, Cindy H. https://orcid.org/0000-0002-6928-3833
DeCaprio, James A. https://orcid.org/0000-0002-0896-167X
Figg, William D. https://orcid.org/0000-0003-2428-5613
Greten, Tim F. https://orcid.org/0000-0002-0806-2535
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
Hodi, F. Stephen
Hughes, Melissa E.
Ligon, Keith L. https://orcid.org/0000-0002-7733-600X
Lin, Nancy
Ng, Kimmie https://orcid.org/0000-0003-0631-1494
Oser, Matthew G. https://orcid.org/0000-0003-2047-0969
Meador, Catherine
Parsons, Heather A. https://orcid.org/0000-0001-8178-6612
Pomerantz, Mark M.
Rajan, Arun https://orcid.org/0000-0003-2776-3385
Ritz, Jerome https://orcid.org/0000-0001-5526-4669
Thakuria, Manisha
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Wen, Patrick Y.
Long, Henry https://orcid.org/0000-0001-6849-6629
Berchuck, Jacob E. https://orcid.org/0000-0002-7607-2428
Szallasi, Zoltan https://orcid.org/0000-0001-5395-7509
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Freedman, Matthew L. https://orcid.org/0000-0002-0151-1238
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0339, W81XWH-22-1-0951, W81XWH-21-1-0358, W81XWH-21-1-0299, W81XWH-18-2-0056)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA137008, P01 CA228696-01A1)
- License Information
-
More Information
Article History
Received: 15 July 2023
Accepted: 21 September 2023
First Online: 21 October 2023
Change Date: 4 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02735-4
Competing interests
: S.C.B., T.K.C. and M.L.F. are co-founders and shareholders of Precede Biosciences. J.D. is a consultant for Kymera Therapeutics and has a sponsored research agreement with Kymera Therapeutics. M.T. served on an advisory board for Incyte. A.N.H. reports research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech and Scorpion Therapeutics and paid consulting for Engine Biosciences, Nuvalent, Oncovalent, TigaTx and Tolremo Therapeutics. J.R. receives research funding from Equillium, Kite/Gilead, Novartis and Oncternal and consults or is on advisory boards for AvroBio, Akron Biotech, Clade Therapeutics, Garuda Therapeutics, LifeVault Bio, Novartis, Smart Immune and TScan Therapeutics. The remaining authors report no competing interests.
